Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | euchromatic histone-lysine N-methyltransferase 2 | Starlite/ChEMBL | No references |
Homo sapiens | tumor protein p53 | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | lysine (K)-specific demethylase 4A | Starlite/ChEMBL | No references |
Homo sapiens | galactosylceramidase | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | histone-lysine n-methyltransferase suv9 | 0.0036 | 0.0036 | 0.0079 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0142 | 0.2867 | 0.2858 |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0036 | 0.0036 | 0.0079 |
Echinococcus granulosus | PHD finger protein rhinoceros | 0.0035 | 0.0013 | 0.0013 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0038 | 0.0074 | 0.0074 |
Plasmodium vivax | SET domain protein, putative | 0.0036 | 0.0036 | 1 |
Schistosoma mansoni | thyroid hormone receptor | 0.0142 | 0.2867 | 1 |
Onchocerca volvulus | 0.0286 | 0.6732 | 1 | |
Echinococcus multilocularis | lysine specific demethylase 5A | 0.0043 | 0.0211 | 0.0199 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0131 | 0.2585 | 0.2575 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0043 | 0.0211 | 0.0695 |
Schistosoma mansoni | hypothetical protein | 0.0131 | 0.2585 | 0.9011 |
Brugia malayi | jmjC domain containing protein | 0.0115 | 0.2159 | 0.3706 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0038 | 0.0074 | 0.0062 |
Trichomonas vaginalis | set domain proteins, putative | 0.0286 | 0.6732 | 0.5 |
Brugia malayi | Pre-SET motif family protein | 0.0036 | 0.0036 | 0.0039 |
Plasmodium falciparum | phd finger protein, putative | 0.0035 | 0.0013 | 0.5 |
Echinococcus granulosus | peregrin | 0.0035 | 0.0013 | 0.0013 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0251 | 0.5802 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.0074 | 0.5 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.2932 | 0.5042 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.2932 | 0.5042 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.2932 | 0.5042 |
Schistosoma mansoni | thyroid hormone receptor | 0.0142 | 0.2867 | 1 |
Giardia lamblia | PHD finger protein 15 | 0.0035 | 0.0013 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.0074 | 0.5 |
Echinococcus multilocularis | histone lysine N methyltransferase SETMAR | 0.0036 | 0.0036 | 0.0023 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.067 | 0.1134 |
Onchocerca volvulus | 0.0036 | 0.0036 | 0.0034 | |
Brugia malayi | Pre-SET motif family protein | 0.0251 | 0.5802 | 1 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.006 | 0.067 | 0.2301 |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0036 | 0.0036 | 0.0079 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0043 | 0.0211 | 0.0343 |
Echinococcus granulosus | lysine specific demethylase 5A | 0.0043 | 0.0211 | 0.0211 |
Echinococcus granulosus | jumonji domain containing protein | 0.0049 | 0.0382 | 0.0382 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0038 | 0.0074 | 0.0215 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0131 | 0.2585 | 0.2585 |
Toxoplasma gondii | histone lysine methyltransferase SET/SUV39 | 0.0036 | 0.0036 | 1 |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0036 | 0.0036 | 0.0079 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0687 | 0.1164 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.0074 | 0.5 |
Echinococcus granulosus | histone lysine methyltransferase setb | 0.0036 | 0.0036 | 0.0036 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0043 | 0.0211 | 0.0695 |
Schistosoma mansoni | hypothetical protein | 0.0038 | 0.0074 | 0.0215 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.0074 | 0.5 |
Echinococcus granulosus | Transcription factor JmjC domain containing protein | 0.0115 | 0.2159 | 0.2159 |
Echinococcus multilocularis | tumor protein p63 | 0.0408 | 1 | 1 |
Echinococcus multilocularis | histone lysine methyltransferase setb histone lysine methyltransferase eggless | 0.0036 | 0.0036 | 0.0023 |
Echinococcus multilocularis | jumonji domain containing protein | 0.0049 | 0.0382 | 0.037 |
Echinococcus multilocularis | Transcription factor, JmjC domain containing protein | 0.0115 | 0.2159 | 0.2148 |
Brugia malayi | jmjC domain containing protein | 0.0043 | 0.0211 | 0.0343 |
Onchocerca volvulus | 0.006 | 0.067 | 0.0977 | |
Schistosoma mansoni | jumonji domain containing protein | 0.0092 | 0.1524 | 0.5293 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0073 | 0.1017 | 0.1735 |
Brugia malayi | hypothetical protein | 0.0038 | 0.0074 | 0.0106 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 0.0036 | 0.0039 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0708 uM | PubChem BioAssay. A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.631 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 8.9125 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 8.9125 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (binding) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.